Recent Updates
Recently added Catalysts
HSIC Positive Sentiment

Henry Schein Reports Strong Second Quarter 2026 Financial Results and Raises FY2026 Guidance

Tuesday, August 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Henry Schein, Inc. reported robust financial results for the second quarter of 2026, highlighting strong sales performance and margin improvements. The company experienced accelerated internal local currency sales growth compared to the previous quarter. Additionally, Henry Schein raised its guidance for the full fiscal year 2026, indicating positive momentum across its business segments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Strong sales performance reported for Q2 2026.
  • Margin improvement driven by operational execution.
  • Increased FY2026 guidance reflects confidence in growth.

Full Press Release Details

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, today reported financial results for the second quarter ended June 27, 2026. “We delivered strong sales performance and margin improvement in the second quarter, driven by sustained momentum across our businesses and solid operational execution by the team. Internal local currency sales growth accelerated compared to the first

Frequently Asked Questions

What were Henry Schein's Q2 2026 financial results?

Henry Schein reported strong sales performance and margin improvements for Q2 2026.

How did Henry Schein perform compared to Q1 2026?

The company experienced accelerated internal local currency sales growth compared to Q1 2026.

What guidance did Henry Schein raise for FY2026?

Henry Schein raised its guidance for the full fiscal year 2026, reflecting positive growth expectations.

ShareAdd on Google
Tags: HSIC Viatris Investor Conferences Healthcare Henry Schein financial results Q2 2026 FY2026 guidance
Last updated: Aug 4, 2026

Biotech snapshot

Cash runway
$138M liquidity · $32M/mo burn
~2 mo
High dilution risk